BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
A hunger for new experiences Narratives: Motivating Travel and Experience - 2Heartfelt Objections to Visit with Your Adored One
- 3Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
- 4These Cities Led Global Jet-Setting In 2025, According To New Data
- 5Step by step instructions to Look at Compact disc Rates: A Thorough Aide
- The Most Compelling Books of the 10 years
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- How grandchildren are stepping up to fill the caregiver gap
- 7 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- Overseeing Individual budgets Successfully
- The most effective method to Amplify Profits from Gold Speculation: Systems and Tips
- Figure out How to Track the Establishment of New 5G Pinnacles
- Step by step instructions to Protect Your Senior Condo for Ideal Wellbeing and Solace
- Vote In favor of Your Favored Sort Of Bevarage
